GSK plc

Equities

GSK

GB00BN7SWP63

Market Closed - London S.E. Other stock markets 11:35:18 2025-12-12 am EST			5-day change	1st Jan Change
1,824.50 ^GBX	+0.19%		+1.08%	+35.50%

Dec. 12	US FDA approves Innoviva's oral antibiotic for gonorrhea	RE
Dec. 12	Surprise UK GDP Contraction Keeps FTSE 100 in the Red	MT

Transcript : GSK plc, Q4 2023 Earnings Call, Jan 31, 2024

Published on 01/31/2024 at 06:00 am EST

S&P Capital IQ

Presenter Speech
Nick Stone (Executives)

Hello, everyone. It's Nick Stone, Head of Investor Relations. Welcome to today's call and webcast. The presentation was sent to our distribution list by e-mail,

This article is reserved for subscribers

Unlock the article : SUBSCRIBE!

Already a customer? Log In

Latest news about GSK plc

Dec. 12	US FDA approves Innoviva's oral antibiotic for gonorrhea	RE
Dec. 12	Surprise UK GDP Contraction Keeps FTSE 100 in the Red	MT
Dec. 12	GSK plc Presents at Citi Annual Global Healthcare Conference 2025, Dec-04-2025
Dec. 12	GSK Says Depemokimab Recommended for EU Approval in Asthma, Rhinosinusitis	MT
Dec. 12	GSK hails positive opinion by EU's CHMP on depemokimab and Nucala	AN
Dec. 12	European health regulator recommends approval for GSK's twice-yearly asthma drug	RE
Dec. 12	Arcus scraps late-stage cancer trial after weak survival data	RE
Dec. 12	GSK Says European Health Agency's Committee Recommends Expanded Approval for RSV Vaccine in Europe	MT
Dec. 12	GSK Gets US FDA Approval for Gepotidacin to Treat Uncomplicated Urogenital Gonorrhoea	MT
Dec. 12	GSK's Arexvy on track for wider age range approval in Europe	AN
Dec. 12	FTSE 100 to rise, UK GDP down, trade deficit spikes	AN
Dec. 12	GSK's RSV Vaccine Bags European Recommendation for Expanded Use	MT
Dec. 12	GSK gets EU regulator backing for expanded use of RSV vaccine	RE
Dec. 12	GSK announces positive CHMP opinion on Arexvy for all adults aged 18 and above	RE
Dec. 12	UK Stocks-Factors to watch on December 12	RE
Dec. 11	GSK Wins US FDA Approval for Uncomplicated Urogenital Gonorrhoea Antibiotic	MT
Dec. 11	GSK Says FDA Approved Oral Treatment for Gonorrhea	DJ
Dec. 11	GSK plc Announces US FDA Approval Of Blujepa For Gonorrhoea Indication	CI
Dec. 11	FDA approves BluJepa for uncomplicated urogenital gonorrhea in some patients	RE
Dec. 11	US FDA expands use of GSK's Blujepa as treatment for gonorrhea	RE
Dec. 11	Fda: approves blujepa for uncomplicated urogenital gonorrhea in some adult & pediatric patients 12 years of age & older - website	RE
Dec. 11	Outgoing GSK CEO Emma Walmsley declares US best place to invest	AN
Dec. 10	Sector Update: Health Care Stocks Rise Premarket Wednesday	MT
Dec. 10	GSK Bolsters Oncology Pipeline with New US FDA Designation, Oxford BioTherapeutics Partnership	MT
Dec. 10	GSK Says Risvutatug Rezetecan Gets FDA Orphan Drug Designation For Small-Cell Lung Cancer Treatment	MT